Saga Diagnostics to Present at Jefferies Global Healthcare Conference in London
SAGA Diagnostics, a pioneer in blood-based cancer testing redefining the standard for ultra-sensitive molecular residual disease (MRD) detection, today announced that SAGA will present at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. The conference is one of the sector’s most influential investor events, bringing together leading private and public healthcare companies with institutional investors, strategic partners, and sector analysts.
SAGA Diagnostics® Announces Medicare Coverage for Pathlight™ MRD Test in Breast Cancer Across All Subtypes
SAGA Diagnostics, a pioneer in blood-based cancer testing redefining the standard for ultra-sensitive molecular residual disease (MRD) detection, today announced that Palmetto GBA’s Molecular Diagnostic Services Program (MolDX) issued a positive coverage decision for the Pathlight MRD test. Pathlight is covered for Medicare beneficiaries for recurrence monitoring in the surveillance setting for up to six years in patients with stage II-III breast cancer, including all subtypes: HR+/HER2-, HER2+ and TNBC.
SAGA Diagnostics® Announces U.S. Commercial Launch of Pathlight™ at ASCO 2025, Setting a New Standard for Ultra-sensitive and Early MRD Detection
SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, today announced the U.S. commercial launch of its Pathlight test for the detection of residual disease and recurrence at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, May 30 - June 3.
